Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 13, 2022 08:02 ET | Source: Novome Biotechnologies, Inc.

Novome Biotechnologies Raises $43.5 Million Series B Financing to Advance its Pipeline of Therapeutically Engineered Microbes

- Funding supports ongoing Phase 2a clinical trial in patients with enteric hyperoxaluria, and pipeline of GEMMs candidates for inflammatory bowel disease - - Financing includes new investors led by...
November 17, 2021 09:02 ET | Source: Novome Biotechnologies, Inc.

Novome Biotechnologies Reports Positive Results from a Phase 1 Study of NOV-001

- Orally-administered Genetically Engineered Microbial Medicine (GEMM) was safe and well tolerated and demonstrated dose-dependent strain engraftment in healthy volunteers - - Results provide...
November 10, 2021 08:32 ET | Source: Novome Biotechnologies, Inc.

Novome Biotechnologies and Genentech Enter into a Strategic Collaboration to Develop Targets Against Inflammatory Bowel Disease

- Collaboration will leverage Novome’s GEMMs platform for colonizing the human gut with therapeutically engineered bacteria - - Novome to receive $15 million upfront payment; potential to receive up...
October 20, 2021 09:02 ET | Source: Novome Biotechnologies, Inc.

Novome Biotechnologies Appoints Bill McLeod as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Novome Biotechnologies, Inc., a clinical-stage biotechnology company developing engineered cellular therapies for the gut, today...
June 30, 2021 09:00 ET | Source: Novome Biotechnologies, Inc.

Novome Biotechnologies Initiates Phase 1/2a Study to Evaluate Therapeutically Engineered Bacteria for the Treatment of Enteric Hyperoxaluria

- NOV-001 is the first therapeutically engineered colonizing gut bacteria to be evaluated in humans - - Phase 1 results anticipated in 2021 and Phase 2a preliminary efficacy results in 2022 - SOUTH...
June 22, 2021 08:00 ET | Source: Novome Biotechnologies, Inc.

Novome Biotechnologies Appoints Dr. Lachy McLean as Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Novome Biotechnologies, Inc., a biotechnology company engineering first-in-class, living medicines for chronic diseases, today...
May 26, 2021 10:00 ET | Source: Novome Biotechnologies, Inc.

Novome Biotechnologies Appoints Dr. David N. Cook and Zachary Hornby to its Board of Directors

SOUTH SAN FRANCISCO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Novome Biotechnologies, Inc., a biotechnology company engineering first-in-class, living medicines for chronic diseases, today announced...
August 12, 2020 10:00 ET | Source: Novome Biotechnologies, Inc.

Novome Biotechnologies Expands Therapeutic Focus and Platform Capabilities with Acquisition of Preclinical Projects and Intellectual Property from Caribou Biosciences and License to CRISPR-Cas9 Foundational Patent Portfolio

− Transfer of Caribou’s novel microbial IP will enable new therapeutic opportunities for Novome − − License to CRISPR-Cas9 intellectual property controlled by Caribou will accelerate the development...
January 07, 2020 10:00 ET | Source: Novome Technologies, Inc.

Novome Biotechnologies Raises $33 Million Series A Financing and Appoints Blake Wise as Chief Executive Officer

− Proceeds to advance lead hyperoxaluria program through Phase 1 clinical proof-of-concept − − Financing led by DCVC Bio and included 5AM Ventures and Alta Partners − SOUTH SAN FRANCISCO, Calif.,...